On the stock market since 2021, it operates in the world of health and science. It has 29 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Debt is low and cash is strong; the finances stand solid.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
The stock has been running stronger than the market lately.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
The stock trades below its recent peak — about 13% off the top. A pullback, not a collapse.
There is $101.1M in the vault; even if every debt were paid off, $100.5M would remain.
Over the last 12 months, company executives reported 21 buys and 7 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $21.67 — 77% above today’s price.
A loss of $59.9M against $0 in annual sales.
At the current pace of spending, the cash lasts about 1.7 years. After that, the company needs to find new money.
On our five-subject report card, CLYM sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: CLYM is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (51/100) says the stock isn’t cheap.